<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666547</url>
  </required_header>
  <id_info>
    <org_study_id>220/12</org_study_id>
    <nct_id>NCT02666547</nct_id>
  </id_info>
  <brief_title>68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis</brief_title>
  <official_title>Value of PET/ CT in the 68Ga-NODAGA-RGD for the Evaluation of the Tumoral Neoangiogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>George Coukos, MD PhD, Head of oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the potential of the 68Ga-NODAGA-RGD for the evaluation of
      neoangiogenesis in patients followed for a neoplastic pathology and for whom a18F-FDG (or
      18F-FET for gliomas) is indicated for initial extension evaluation or suspicion of recurrent
      tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the value of 68Ga-NODAGA-RGD PET/CT for detection of
      neoangiogenesis at level of neoplastic processes, in patients, compared to 18F-FDG PET/CT
      (tumors other than glioma) or 18F-FET PET/CT (patients affected by glioma) and to determine
      the respective diagnostic contribution of every technique.

      Every patient will undergo a routine 18F-FDG (or 18F-FET) PET/CT followed by a
      68Ga-NODAGA-RGD PET / CT specific for the study within the next 7 days.

      (each image procedure duration: 2h)

      The criteria of primary evaluation for each of the techniques will be defined:

        -  On the images of PET/CT: SUVmax, SUVmoyen, VOI ( mL ), SUV41 % ratio [mean SUV of pixels
           ≥ 41 % of the SUVmax] of lesions / SUV

        -  On the images of CT: size of the lesions measured in 3D (axial, coronal and sagittal),
           density in Hounsfield unit (HU)

      The 18F-FDG/18F-FET and 68Ga-NODAGA-RGD PET / CTs will be analyzed at first separately then
      will be compared according to the methods described in the analysis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of each method of imaging for detection of tumors</measure>
    <time_frame>within 10 days</time_frame>
    <description>To compare the capacity of each of the techniques and their combination to detect tumors, to determine the composition of these tumors (neoangiogenesis, metabolism, necrosis), their extension, the changes due to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ROC analysis and comparison of areas under the curve</measure>
    <time_frame>Within 10 days</time_frame>
    <description>A ROC analysis will be realized as well as a comparison of AUCs, to determine the superiority of a method compared to the other one, using a parametric test comparing of the AUC curves and ROC curves respectively by an established algorithm. The criteria of interpretation and positivity will be defined in a standard way on the images 18F-FDG / 18F-FET and 68Ga-NODAGA-RGD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison 68Ga-NODAGA-RGD to standard routine extension imaging assessments</measure>
    <time_frame>within 10 days</time_frame>
    <description>The sensibility for detection of tumor by the 68Ga-NODAGA-RGD will be assessed and compared with the standard routine extension assessements including 18F-FDG PET/CT or18F-FET PET/CT, CT or any other complementary exam (US, MRI)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pathological Angiogenesis</condition>
  <arm_group>
    <arm_group_label>68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active Comparator: 68Ga-NODAGA-RGD radiotracer All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT or a 18F-FET PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>68Ga-NODAGA-RGD PET/CT</intervention_name>
    <description>200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull</description>
    <arm_group_label>68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-FDG PET/CT</intervention_name>
    <description>3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body</description>
    <arm_group_label>68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-FET PET/CT</intervention_name>
    <description>200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull</description>
    <arm_group_label>68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≤ 85 years old

          -  Karnofsky index: ≥ 80%

          -  Patients presenting a neoplasic pathology, histologically proven, known to have
             expressed integrin αvβ3and for which a 18F-FDG (or a 18F-FETfor glioma) is indicated :
             (1) glioma (WHO I, II-IV), (2) malignant melanoma, (3) cancer of upper respiratory
             tract, (4) breast cancer,(5) bone metastasis, (6) ovarian cancer, (7) lung cancer,(8)
             non-Hodgkinian malignant lymphoma with extra- lymphatic nodes extension, (9)
             neuroendocrine tumors, (10) pancreatic cancer,(11) oesophagus cancer,(12) stomach
             cancer. 10 patients will be included per type of cancer.

          -  Informed consent signed

        Exclusion Criteria:

          -  Incapacity to sign the informed consent

          -  Pregnancy, breastfeeding

          -  Age &lt;18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John O Prior, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lausanne University Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John O Prior, MD, PhD</last_name>
    <phone>+41 21 314 43 48</phone>
    <email>john.prior@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Geldhof, BSc</last_name>
    <phone>+41 21 314 4346</phone>
    <email>christine.geldhof@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois, Nuclear Medicine</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2016</study_first_submitted>
  <study_first_submitted_qc>January 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>November 13, 2016</last_update_submitted>
  <last_update_submitted_qc>November 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>John O. Prior</investigator_full_name>
    <investigator_title>Chief Nuclear Medicine Department</investigator_title>
  </responsible_party>
  <keyword>68Ga-NODAGA-RGD</keyword>
  <keyword>18F-FDG</keyword>
  <keyword>18F-FET</keyword>
  <keyword>PET/CT</keyword>
  <keyword>neoangiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

